Drug intelligence / Profile preview

Yiqi Weixue granules

Development stage: Unknown
Lead developer: Red Coral Pharmaceutical
Administration: Oral

Overview

Yixuebao (益气维血颗粒) is a Traditional Chinese Medicine (TCM) oral granule product developed and marketed by Guangdong Hongshanhu Pharmaceutical (also known as Red Coral Pharmaceutical Group). It is indicated for the treatment of anemia and as a general blood tonic, operating under the TCM principles of 'Yiqi' (supplementing Qi) and 'Weixue' (supplementing blood). The product is an approved pharmaceutical in China and is part of a broader product line that includes capsules. While its specific molecular targets are not defined in conventional Western pharmacological terms, it is widely used for its blood-tonifying properties.

Brand names: 益雪宝Yixuebao
Other names: 益气维血颗粒Yixuebao Yiqi Weixue granules

Beyond the preview

Go deeper on Yiqi Weixue granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yiqi Weixue granules.

Explore the full profile